BMYscreen was created under the impulsion of the team «Organelles, stress and cancer» led by Dr. Eric Chevet within the laboratory INSERM U1053. Our team comprises experienced PhD and involves scientific consultants and collaborators in the field of biotechnologies, cell biology, chemistry, oncology and metabolism.
PhD. Founding member. Scientific Director
Eric Chevet is Research Director at INSERM. After a Ph.D. in Molecular Cell Biology from the University of Paris in 1996 and a post-doctoral fellowship at McGill University (Canada), he established his own laboratory at McGill University in 2001 before going back to France in 2006. For the past 10 years he developed a great expertise about the role of endoplasmic reticulum stress signaling and proteostasis control in cancer development.
Eric has published more than 100 articles in leading scientific journals such as Cell, Nat Genetics, PNAS, Mol Cell, PLoS Biol, EMBOJ, Cancer Res and holds several patents.
PhD. Founding member. Director of BMYscreen « cancer » dept.
Saïd has over 20 years of research experience and has authored >35 publications in the field of signaling and cancer. He is currently heading a biotechnology platform at INSERM to developp projects in the field of oncology and drug discovery. He obtained his PhD in biochemistry and cellular biology in 1996 at the University of Caen. Said became then group leader at AFSSA (French Agency for Food Safety) developing projects in infection, immunity and vaccination. In 2007, Saïd joined the Chevet lab to focus on endoplasmic reticulum stress and cancer.
Said is an expert in the development and application of methods monitoring biomolecular interaction and drug screening.
PhD. Founding member. “Cellule de transfert” manager
Stéphanie Lhomond received her Ph.D. in Cell Biology and Physiopathology from the French Institute of Health and Medical Research (INSERM) in 2014, in the Chevet lab (Bordeaux, France). During four years, she worked on endoplasmic reticulum stress in cancer and developed expertise in oncology especially in glioblastome and hepatocellular carcinoma as well as in the endoplasmic reticulum field. Since May 2014, Stéphanie manages the “cellule de transfert de technologie” part of BMYscreen (ADERA).
She is experienced in molecular biology and stresses monitoring and developed skills in project design, management and business.
PhD. Founding member. Chief technology officer
Nicolas Dejeans has 10 years of experience in the field of cell stress. He received his Ph.D. in Molecular Cell Biology from the French National Institute of Agricultural Research (INRA) (Clermont-Ferrand, France) in 2008. He subsequently developed expertise in cancerology and pharmacology as a postdoctoral fellow at the Louvain Drug Research Institute (LDRI) (Brussels, Belgium). In 2011 he joined the Chevet lab at INSERM.
Nicolas is an expert in the development and application of methods monitoring molecular stress in pharmaceutical and pathological conditions.